v3.26.1
Segment Reporting (Tables)
 3 Months Ended
Apr. 03, 2026
Segment Reporting [Abstract]  
Schedule of Segment and Consolidated Net Income, Including Significant Segment Expenses
The segment and consolidated net income, including significant segment expenses were as follows (in thousands):

Three Months Ended March 31,

20262025
Revenues$610,812 $555,447 
Less:
Cost of goods sold19,953 19,172 
Drug discovery19,476 18,253 
Development135,715 153,217 
Selling, general, and administrative122,870 120,775 
Other segment items(1)
61,238 57,416 
Interest income(16,127)(19,076)
Provision for income taxes57,220 46,074 
Segment and consolidated net income$210,467 $159,616 
_________________
(1) Other segment items include stock-based compensation, other research and development expenses, including the allocation of general corporate costs to research and development services and development cost reimbursements in connection with certain of our collaboration arrangements, and other income (expenses), net.